The 10 Most Valuable Patents Ever Granted — And What Made Them Worth Billions

Some patents protect inventions. Others protect monopolies. The difference is whether competitors can invent around the claims — or whether the claims are so fundamental that every alternative is either worse or infringing.

Here are 10 patents that created the latter kind of protection, ranked by the revenue and market value they enabled.

1. US5272135 — Lipitor (Atorvastatin)

Assignee: Warner-Lambert (Pfizer) · Revenue: $125B+

The best-selling drug in history. Lipitor's patent covered the specific calcium salt of atorvastatin — a statin that lowered LDL cholesterol more effectively than any competitor. The patent's strength came from covering not just the molecule but the specific crystalline form that made it bioavailable. Generic manufacturers couldn't just make "atorvastatin" — they had to match the exact polymorph, which Pfizer defended aggressively.

2. US6285999 — PageRank

Assignee: Stanford University (licensed to Google) · Value: Enabled Google's entire search monopoly

Not the search engine itself — the ranking algorithm. PageRank modeled the web as a graph where links were votes, and pages with more votes from important pages ranked higher. The patent was so broad it covered essentially any link-analysis-based ranking method. Microsoft and Yahoo spent years trying to develop ranking systems that didn't infringe. By the time they did, Google had won.

3. US6090382 — Humira (Adalimumab)

Assignee: BASF (AbbVie) · Revenue: $20B+/year at peak

The first fully human monoclonal antibody. Unlike earlier antibody drugs derived from mice (which caused immune reactions), Humira was built from human antibody genes. AbbVie extended its exclusivity through a dense thicket of formulation and manufacturing patents — over 100 patents protecting every aspect of production. The result: 20 years without a biosimilar competitor in the US.

4. US4683195 + US4683202 — PCR (Polymerase Chain Reaction)

Assignee: Cetus Corporation · Value: Enabled the entire molecular diagnostics industry

Kary Mullis's invention lets you take a single DNA molecule and make billions of copies. Every COVID test, every genetic screening, every crime-scene DNA analysis depends on PCR. The patents were sold to Roche for $300M — a bargain, given that the global PCR market is now $10B+/year.

5. US5521184 — Gleevec (Imatinib)

Assignee: Ciba-Geigy (Novartis) · Revenue: $4.7B/year at peak

The first drug that targeted a specific cancer-causing protein rather than just killing fast-dividing cells. Gleevec turned chronic myeloid leukemia from a death sentence into a manageable condition. The patent covered the specific tyrosine kinase inhibitor molecule — and because it was the first of its class, there was no obvious alternative chemistry to invent around.

6. US7479949 — Multi-Touch

Assignee: Apple Inc · Value: Defined the smartphone interface

Not "a touchscreen" — those existed for decades. This patent covered the specific gesture-detection system that could distinguish a scroll from a tap from a pinch, using heuristics about finger movement patterns. Every smartphone shipped after 2007 either licensed this approach or spent years developing workarounds.

7. US4237224 — Recombinant DNA (Cohen-Boyer)

Assignee: Stanford University · Value: Enabled the entire biotech industry

The fundamental method for splicing genes into bacteria to produce proteins. Licensed to over 400 companies, generating $255M in royalties for Stanford. Every biologic drug — insulin, growth hormone, monoclonal antibodies — starts with this technique. The patent was deliberately licensed cheaply and non-exclusively to encourage adoption.

8. US8697359 — CRISPR Gene Editing

Assignee: Broad Institute (MIT/Harvard) · Value: Still unfolding — potentially trillions

The method for using Cas9 to edit specific DNA sequences in living cells. The patent battle between Broad and UC Berkeley was the most expensive in biotech history. The winner controls the foundational IP for editing the human genome — with applications in every disease with a genetic component.

9. US9402913 — Sovaldi (Sofosbuvir)

Assignee: Gilead/Pharmasset · Revenue: $10B+ in first year

The first true cure for Hepatitis C — >95% cure rate with a pill, replacing a year of painful interferon injections with ~50% success. Gilead paid $11B for Pharmasset to acquire this patent. They recouped it in 18 months.

10. US8580275 — CAR-T Cell Therapy

Assignee: MSKCC/Juno · Value: Opened a new cancer treatment modality

The method for engineering a patient's own T-cells to recognize and kill cancer cells. Not a drug — a process for reprogramming the immune system. The first CAR-T therapies (Kymriah, Yescarta) cost $373,000–$475,000 per patient — and worked when nothing else did.

The pattern

Every patent on this list shares one trait: the claims covered the mechanism, not the outcome. Lipitor didn't claim "lowering cholesterol" — it claimed the specific molecule. PageRank didn't claim "ranking web pages" — it claimed the specific link-analysis algorithm. Multi-Touch didn't claim "a touchscreen" — it claimed the specific gesture-recognition heuristics.

If your patent application describes what your invention does instead of how it does it, you're writing a marketing document, not a patent.

What actually makes a patent valuable

The dollar figures above are downstream of a few structural traits. A patent is worth a lot when:

• The claims are broad but valid. Breadth means more products infringe; validity means the claims survive a challenge. The most valuable patents thread that needle — broad enough to cover every commercial alternative, specific enough to withstand the prior art.
• There is no good way to design around them. A patent you can sidestep with a minor change is worth little. Lipitor's value came from claiming the specific molecule patients actually needed; PageRank's from covering essentially any link-analysis ranking method. In both, the alternatives were either worse or infringing.
• They block a whole field. Foundational patents — PCR, recombinant DNA, CRISPR — don't protect one product; every downstream company in the field needs a license. That turns the patent into a tollbooth on an entire industry.
• They have term left. Value is measured over remaining life. A blockbuster with fifteen years to run is worth far more than the same patent with two years left — which is why expiry dates and term extensions matter so much in pharma.

Why drug patents dominate the list

Notice how many of the ten are pharmaceuticals. That is not a coincidence. A small-molecule drug can be protected by a composition-of-matter claim — a claim to the molecule itself. There is usually exactly one molecule that works, so a competitor cannot invent around it without making a different (and unproven) drug. Software and method patents protect a way of doing something, and there are usually many ways, so they are far easier to design around. Composition-of-matter exclusivity, plus the enormous revenue concentrated in a single approved product, is why pharma patents sit near the top of almost every "most valuable" ranking.

Patent thickets: stacking exclusivity

The headline patent is rarely the whole story. Humira's maker surrounded the original antibody patent with over a hundred secondary patents — on formulations, manufacturing processes, dosing regimens, and uses — so that even after the core patent expired, a biosimilar competitor faced a wall of remaining claims to clear. This "patent thicket" strategy is legal and common, and it is a major reason blockbuster drugs hold off competitors for far longer than the 20-year term of any single patent.

A different kind of value: standard-essential patents

Some patents are valuable not because they exclude competitors but because everyone is required to use them. If a patent reads on an industry standard — a cellular protocol, a video codec like H.264, a Wi-Fi feature — then every device implementing that standard infringes it. In exchange for inclusion in the standard, the owner typically commits to license on FRAND terms (fair, reasonable, and non-discriminatory). The value comes from collecting a small royalty across an entire industry's worth of devices, year after year — a fundamentally different model from the winner-take-all exclusion of a drug patent.

The honest counterpoint: most patents are worth nothing

For perspective: the patents on this list are extraordinary outliers. The vast majority of patents are never licensed, never litigated, and quietly lapse when their owners stop paying maintenance fees. Studies of patent litigation have found that only on the order of 1–2% of patents are ever asserted in a lawsuit, and a large share of granted patents are abandoned before their full term. Patent value is extremely concentrated — a tiny number of patents capture almost all of the economic value, and the rest are, in cold financial terms, paperweights. The lesson for inventors is not "patents are worthless," but "a patent is only as valuable as the claims you fought for and the market you can actually exclude."